India’s ₹99.7 lakh crore capex pipeline surges 39%—but can projects become real investment?

 

BIZ MASALA  |  BUSINESS • MARKETS • PEOPLE • INSIGHT

Union Bank of India Research sees a sharply larger private investment pipeline, but a slower rise in project numbers and concentration in a few sectors and states raise questions about how broad the recovery really is.

By Biz Masala Desk  |  October 22, 2026

Editorial illustration. Figures refer to the reported private-sector project pipeline as of September 2026.

India’s planned private-sector capital expenditure pipeline climbed 39% year-on-year to ₹99.7 lakh crore in September 2026, according to a Union Bank of India (UBI) Research report. The headline figure signals a much larger pool of proposed investment. But the report’s finer detail points to a more qualified story: over two years, the value of the pipeline grew 87%, while the number of projects increased by 18%. Bigger project costs, rather than a comparable expansion in project count, account for much of the rise.

That distinction matters. A pipeline measures projects that have been announced or planned; it is not the same as money already spent, factories operating or jobs delivered. For the economy, the decisive test is how many proposals secure finance and approvals, reach construction, connect to infrastructure and ultimately begin productive operations.

The headline numbers—and the caveat

Source: UBI Research figures as reported on 22 October 2026. Pipeline figures are not actualised expenditure.

The report says announced project costs increased by ₹46.4 lakh crore over the past two years, compared with an addition of ₹7 lakh crore during the eight years to March 2022. The current pipeline is reported at 4.1 times its March 2014 level. These comparisons show the scale of the change in project intentions, but they do not by themselves reveal the proportion that will be completed on time.

A narrow set of sectors is doing much of the lifting

Information-technology-enabled services (ITES) and conventional power together accounted for 87% of the net annual increase in the pipeline. ITES added ₹16.8 lakh crore and conventional power ₹7.6 lakh crore. The ITES pipeline alone rose from ₹2.2 lakh crore to ₹18.9 lakh crore in a year, covering 160 projects, according to the report.

Across the outstanding pipeline, manufacturing accounted for ₹41.3 lakh crore and electricity for ₹32.2 lakh crore. Together, the two represented 74% of the total. Services recorded the fastest annual growth rate, rising 347% to ₹21.9 lakh crore. The sector mix underlines the importance of industrial capacity and energy infrastructure—but also means the investment outlook is sensitive to whether large projects in these areas proceed.

Investment growth is concentrated geographically

Maharashtra remained the largest destination for announced private investment, with projects worth ₹28.6 lakh crore—about 29% of the pipeline. The report also found that Maharashtra, Andhra Pradesh, Telangana, Odisha and Uttar Pradesh together accounted for 94% of the pipeline’s annual increase.

For Andhra Pradesh and Telangana, this is an important signal of their presence in the current investment pipeline, but it should not be read as proof that all announced projects will materialise. States compete not only to attract proposals, but to provide predictable approvals, reliable power and transport links, suitable land, skilled workers and a timely route from announcement to operation. Local supplier participation and the distribution of jobs will determine how widely the benefits are felt.

The power-sector execution question

UBI Research highlighted a striking gap between planned investment in power generation and transmission: around ₹32 lakh crore for generation against just ₹0.17 lakh crore for transmission. The imbalance raises questions about whether grid capacity and power evacuation arrangements will keep pace with planned generation projects.

For lenders, a large pipeline can create opportunities, but the bank’s report cautions against judging projects on headline values alone. Financing needs, implementation readiness, grid connectivity and execution prospects all matter. Projects that are delayed or cannot deliver output as planned may not produce the expected economic returns.

What to watch next

·       Conversion rate: how many announced projects secure approvals, funding and construction milestones.

·       Project count: whether the number of projects starts to rise more in line with total proposed costs.

·       Sector balance: whether investment broadens beyond ITES and conventional power.

·       State-level delivery: whether announced investments lead to operating facilities, supplier contracts and local employment.

·       Power infrastructure: whether transmission and evacuation capacity catch up with generation plans.

The Biz Masala takeaway

India’s private capex pipeline is expanding rapidly, but its size alone cannot settle the question of whether a broad-based investment cycle has taken hold. The reported figures show concentration by sector and geography, while project counts have grown much more slowly than project value. The next phase will be judged by execution: money deployed, projects commissioned, productive capacity added and jobs created. For businesses and policymakers, the task is to turn a formidable pipeline into real economic activity.

Editorial distinction: proposed pipeline values should not be presented as completed investment or actual expenditure.

 

BIZ MASALA  |  BUSINESS • MARKETS • PEOPLE • INSIGHTS

BIZ MASALA

Business. Markets. People. Insight.

Comments

Post a Comment

Popular posts from this blog

THE GREAT INDIAN CINEMA RESET

Image
  BIZ MASALA | BUSINESS. MARKETS. PEOPLE. INSIGHT. From Bollywood's dominance to the pan-India blockbuster: how regional cinema, streaming and changing audience behaviour rewrote the business of Indian films By Murthy ASR | Biz Masala | 17 October 2026 Hero artwork created for this story; conceptual illustration, not a documentary photograph. The opening scene: A business no longer controlled by one city For decades, Mumbai occupied the commanding heights of Indian cinema. Hindi films enjoyed cultural and commercial reach, while Telugu, Tamil, Malayalam and Kannada cinema had powerful home markets but more limited national distribution. S. S. Rajamouli's Baahubali: The Beginning (2015) helped demonstrate that a film rooted in one linguistic industry could travel nationally when storytelling, scale, marketing and distribution worked together. Baahubali 2 and later successes from Telugu and Kannada cinema reinforced the lesson. A decade later, dubbed releases are ...
Read more

SINGARENI COAL PUZZLE : THE CONTRACT QUESTION

Image
  What the CAG found in Singareni’s coal operations—and what remains to be answered By Murthy ASR   |   Biz Masala Investigative Series The audit trail is public. The follow-through is the next question. Singareni Collieries Company Limited (SCCL) is jointly owned by the Governments of Telangana (51%) and India (49%). It is not simply a mining company: its coal feeds power generation and industry, and its operating decisions have consequences for workers, consumers and public finances. A subject-specific compliance audit by the Comptroller and Auditor General of India (CAG), covering overburden removal, coal transportation and stowing-material contracts during 2018–19 to 2022–23, put several contract-design and operational questions on the public record. The report was tabled in the Telangana legislature on 30 March 2026. Its findings are historical and specific to the contracts and periods examined; they do not, by themselves, establish the cause of later pro...
Read more

WHO TESTS THE MEDICINES INDIA MAKES?

Image
  BIZ MASALA SIGNATURE STORY Inside the business of pharmaceutical testing laboratories — the money, the market and the science behind a medicine’s quality By Murthy ASR   |   18 October 2026 Illustrative editorial image: pharmaceutical analytical testing laboratory. A medicine may be manufactured on a modern production line, packed in a clean facility and shipped across the world. But before a batch can be trusted, its quality has to be demonstrated. Behind that assurance is a less visible industry: laboratories that test ingredients, finished formulations, impurities, stability and, where relevant, biological characteristics. For India, this is more than a technical service. The country’s pharmaceutical manufacturers supply domestic patients and regulated markets overseas. Their products must meet specifications, documentation requirements and regulatory expectations that vary by medicine and destination. Testing laboratories help generate the evidence on ...
Read more